biopharma-reporter3d
Amylyx Pharmaceuticals gets FDA go ahead for phase 1 ALS trial
The Massachusetts based biotech will now press ahead with human trials for its antisense oligonucleotide (ASO) therapy, ...
Neurological conditions affect 3.4B people worldwide. What about Canada?
Joshua Armstrong, a research scientist at the Alzheimer Society of Canada (ASC), told Global News the Lancet study shows how ...
GEN5d
Genetic Reanalysis Provides New Rare Disease Diagnoses
Study highlights use of techniques such as long-read genome sequencing, optical genome mapping, and RNA sequencing for rare ...
REGENERON EXPANDS PRESENCE IN CANADA BY OPENING ITS FIRST HEADQUARTERS TO BETTER SERVE NEEDS OF CANADIANS WITH SERIOUS DISEASES
Regeneron Canada Company today officially opened its first headquarters that will allow it to better serve the needs of ...
Microelectrode Array In Vitro Market to Reach US$ 25.67 Million by 2031, Driven by Neuroscience and Animal Testing Alternatives
The global microelectrode array in vitro market is witnessing significant growth owing to increasing demand for ...
Stockhouse6d
REGENERON EXPANDS PRESENCE IN CANADA BY OPENING ITS FIRST HEADQUARTERS TO BETTER SERVE NEEDS OF CANADIANS WITH SERIOUS DISEASES
Facilities for Regeneron Canada in thriving Mississauga/GTA biotech hub signal ... cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare ...
Investors Purchase Large Volume of Put Options on Xenon Pharmaceuticals (NASDAQ:XENE)
Xenon Pharmaceuticals Inc. (NASDAQ:XENE – Get Free Report) was the recipient of some unusual options trading on Wednesday. Traders bought 4,063 put options on the stock. This is an increase of ...
Wane4d
Bird flu linked to waterfowl deaths around Indiana; DNR urges caution for hunters
ALLEN COUNTY, Ind. (WANE) – The recent deaths of waterfowl around the state — including in Allen County — are linked to bird ...
bovnews5d
A Major Breakthrough on the Horizon for Helius Medical (HSDT): What’s Next?
Helius Medical’s YTD stock performance is +4.89%, a figure that outpaces the S&P 500’s YTD performance of +1.52%. This points to a promising period for Helius, showing that despite the overall ...
Wedbush Weighs in on Biogen’s Q4 Earnings (NASDAQ:BIIB)
Stock analysts at Wedbush lowered their Q4 2024 earnings estimates for Biogen in a research report issued on Thursday, January 23rd. Wedbush analyst L. Chico now forecasts that the biotechnology ...